July 19, 2024

Antibody Drug Conjugates (ADCs) is the largest segment driving the growth of Antibody Drug Conjugates Market

Antibody drug conjugates are monoclonal antibody-drug conjugates that deliver cytotoxic molecules to tumor sites. They combine the specific binding of antibodies and the potent cytotoxic effect of chemotherapy. This allows targeted drug delivery and minimizes off-target side-effects.

The global Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 Bn in 2023 and is expected to exhibit a CAGR of 14 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the ADC market is the growing demand for highly potent cytotoxic payloads that can deliver the desired therapeutic efficacy at lower dosing. This is significant as it helps to reduce side effects. Another major trend is the development of linker technologies that provide optimal drug-antibody ratio and release the payload inside cancer cells. Advanced linkers that are stable in the bloodstream but release the drug upon internalization into cells have shown promising results in clinical trials. This has boosted research activities aimed at developing novel linker technologies.

SWOT Analysis
Strength: The technology behind antibody drug conjugates has advanced significantly allowing for more targeted drug delivery to cancer cells with less toxicity to normal cells. This helps improve patient’s outcomes.
Weakness: Developing ADCs requires significant capital investment and expertise in antibody and drug development. There is risk in ensuring the linker system maintains stability and releases the drug inside cancer cells.
Opportunity: The growing prevalence of cancer worldwide presents a large market opportunity for more effective targeted therapies. Successful ADCs gaining approvals can generate blockbuster revenues.
Threats: Biosimilars may erode sales of leading ADCs when patents expire. Delays or failures in late stage clinical trials also pose risks to expected revenues.

Key Takeaways
The global Antibody Drug Conjugates Market is expected to witness high growth, exhibiting CAGR of 14% over the forecast period, due to increasing demand for targeted cancer therapies with improved safety profiles. North America is expected to dominate the global ADC market over the forecast period due to rising cancer prevalence, large healthcare spending and presence of key market players in the region. Europe and Asia Pacific are also likely to witness high growth rates owing to growing research activities, increasing disposable incomes and healthcare investments in developing nations.

Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd. Leading players are focusing on expanding their product pipelines through collaborations and M&A activities to strengthen their market position.

Regional analysis North America accounts for the largest share of the global ADC market and is expected to dominate with a share of over 35% by 2030 owing to rising cancer prevalence, large healthcare spending and presence of key market players in the region. Europe and Asia Pacific are also likely to witness high growth rates owing to growing research activities, increasing disposable incomes and healthcare investments in developing nations.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it